{"id":88851,"date":"2026-10-27T17:45:00","date_gmt":"2026-10-27T17:45:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=88851"},"modified":"2026-10-28T01:59:08","modified_gmt":"2026-10-28T01:59:08","slug":"tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/","title":{"rendered":"TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight"},"content":{"rendered":"<p><em>The TGFb inhibitor clinical trial analysis report delivers important insights into ongoing research on 30+ TGFb inhibitors in the pipeline, clinical strategies, upcoming therapeutics, and commercial analysis.<\/em><\/p>\n<p align=\"justify\">New York, USA, Oct.  27, 2026  (GLOBE NEWSWIRE) &#8212; <b>TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight\u00a0<\/b><\/p>\n<p align=\"justify\"><b><i>The TGFb inhibitor clinical trial analysis report delivers important insights into ongoing research on 30+ TGFb inhibitors in the pipeline, clinical strategies, upcoming therapeutics, and commercial analysis.<\/i><\/b><\/p>\n<p align=\"justify\">DelveInsight\u2019s TGFb Inhibitors Pipeline Insight 2026 report provides comprehensive global coverage of pipeline therapies for TGFb inhibitors across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the TGFb inhibitors domain.<\/p>\n<p align=\"justify\"><b>TGFb Inhibitors Clinical Trial Analysis Summary<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">DelveInsight\u2019s TGFb inhibitors pipeline report depicts a robust space with<b> 25+ <\/b>active players working to develop <b>30+ <\/b>pipeline TGFb inhibitors.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Key TGFb inhibitor companies, such as<b> Takeda, Hansoh Pharma, Akeso Biopharma, EpicentRx, Scholar Rock, Sirnaomics, iOnctura, Oncotelic Inc., MedPacto, Inc., <\/b>and others, are evaluating new TGFb inhibitor drugs to improve the\u00a0treatment landscape.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Promising pipeline TGFb inhibitors such as<b> Elritercept (HS-20106), AK130, AdAPT-001, SRK-181, STP707, STP705, STP355, IOA-359, OT-101, Vactosertib, <\/b>and others are under different phases of TGFb inhibitors clinical trials.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Approximately 18+ TGFb inhibitor drugs are in the mid and early stages of development.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Key indications for TGFb inhibitors under development include <b>Anemia, Myelofibrosis, Glioblastoma, Colorectal cancer, Solid tumors, Pancreatic cancer<\/b>, <b>Basal Cell Carcinoma, Squamous Cell Carcinoma, Breast cancer <\/b>and others.<\/li>\n<\/ul>\n<p align=\"justify\">Request a sample and discover the recent advances in TGFb inhibitor drugs @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=asCk55Ski7W73jICmus4lGfgi_8lEOk-LRmO1kkeJJtEuX3HPB2m6i8eQZvx49K61SV_V--aff7-iJY1V8pCbehKWS2gAV-FDeHSNcxWQ2klLn-ssZCCyeuWxjy6WutyREXsjHWAJJLrs3HkU0sd1_nEvSRSXakfDkBABu63fBNGRLR_QsT8MfT2psw5h0clvqzYeJmFsLwtaJ5KPHjDCpeX6e437voSB5O-MwtpbrrnAKOtYlrbRqp-1rSqAKx5jPG7iaiFI18KmK_JvZsBhR-m8SvcUcTDJRMRWymA3gUv1g7tIyhGaYCOJ0Kaot3Oko055D_CJPkgGS6D1sDsGR_erAud-0uF66hG8HaWxkEVry6aKGsrv_X9buwel7VdHqB84lac0H4XgguUDuLuBg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>https:\/\/www.delveinsight.com\/report-store\/transforming-growth-factor-beta-tgfb-inhibitor-pipeline-insight<\/b><\/a><\/p>\n<p align=\"justify\"><b>What are TGFb Inhibitors?<\/b><\/p>\n<p align=\"justify\">TGF-\u03b2 inhibitors are a class of therapeutic agents designed to block the activity of transforming growth factor-beta (TGF-\u03b2), a multifunctional cytokine involved in regulating cell growth, differentiation, immune responses, tissue repair, and extracellular matrix formation. Dysregulated TGF-\u03b2 signaling can contribute to tumor growth, immune suppression, fibrosis, and abnormal tissue remodeling. By inhibiting TGF-\u03b2 ligands, receptors, or downstream signaling pathways, these therapies aim to reduce pathological signaling and restore normal cellular and immune functions. TGF-\u03b2 inhibitors are being investigated across a range of therapeutic areas, particularly oncology and fibrotic diseases, with approaches including monoclonal antibodies, ligand traps, receptor kinase inhibitors, and antisense or other targeted agents. In cancer, TGF-\u03b2 inhibition may help overcome tumor-associated immune suppression and potentially enhance the activity of other anticancer therapies, while in fibrotic disorders, it may limit excessive extracellular matrix deposition and tissue scarring.<\/p>\n<p align=\"justify\"><img decoding=\"async\" alt=\"\" data-mce-style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/a5662871-8594-43d9-8c96-c52112f45498\/tgfb-inhibitors-pipeline.jpg\" style=\"display:block; margin-left:auto; margin-right:auto;\" data-dpi=\"96\" data-filename=\"TGFb-Inhibitors-Pipeline.jpg\" \/><\/p>\n<p align=\"justify\">Find out more about TGFb inhibitor drugs @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LowcUB4kr_TZV8TO1UQiXiMcEKI5oCAymIlkbNFAlEDUNsTMxALNIGn1yFAlQKK9dLEnc63hPyHdituCTSK2ZYEksJZrQggcgM5DDM_i0HAI621TDSHmEvqbgHMgArEPS2eSEszFhW8PcQqhGss1i_0qigTdtrHWDvZCi2-v1ZdP35853sabRzTdTmMjC9jJ1x5XL8FTA4h3rCL_IRDY3g==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>TGFb Inhibitors Analysis<\/b><\/a><\/p>\n<p align=\"justify\"><b>A snapshot of the Pipeline TGFb Inhibitor Drugs mentioned in the report:<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Drugs<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Company<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Phase\u00a0<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Indication<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>RoA<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Elritercept (HS-20106)<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Takeda\/Hansoh Pharma<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">III<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Anemia; Myelofibrosis<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">SC<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">OT-101<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Autotelic\/Oncotelic Therapeutics<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">III<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Glioblastoma<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Intracranial microperfusion ;Intratumorally\/Intravenously<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Vactosertib<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">MedPacto<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">II<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">mCRC; NSCLC; r\/rMM, Desmoid<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Oral<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">AdAPT-001<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">EpicentRx<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">II<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Sarcoma; Refractory Solid tumors<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Intratumoral injection<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">AK130<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Akeso Biopharma<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">II<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Pancreatic cancer<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">IV infusion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">STP707<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Sirnaomics<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">I<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Solid tumors<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">IV infusion<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Learn more about the emerging TGFb inhibitors @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LowcUB4kr_TZV8TO1UQiXmNY1kB_XwCKl0pvn5GvvqkiV27RbC-rHEQi67Q43WGO7mpDq1zFCNZHckPRg9DW5tUIVtTwN5cVp4RTv0PdwIsU9VtNT9P96ezaCGbOVISGom1saBW-KoOJuMb5FfXonheSYfqTHz-bHKFy4FVIkpLbtWzHqrxfi2AakwcuSW72vxnrnMLTIU40T_kFa79trGQVfRXrC0LJsKVhxAP-tzI=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>TGFb Inhibitors Clinical Trials<\/b><\/a><\/p>\n<p align=\"justify\"><i>Arunima Dabral, Associate Consultant of Competitive Intelligence and Consulting at DelveInsight, said that the TGF-\u03b2 therapeutic landscape is expected to evolve toward more selective, context-specific, and precision-driven pathway modulation, supported by increasing clinical development and strategic investment across oncology, hematology, pulmonary hypertension, and other disease areas. The field is gradually moving beyond broad pathway inhibition toward approaches designed to improve target specificity, tissue selectivity, therapeutic window, and clinical tolerability, while combination strategies are gaining importance as developers seek to address the complex and interconnected roles of TGF-\u03b2 signaling in immune suppression, fibrosis, angiogenesis, and abnormal tissue remodeling. Continued advancement into late-stage clinical development is expected to provide greater validation of the pathway, although challenges related to biological complexity, patient selection, systemic safety, and translating pathway engagement into meaningful clinical outcomes remain. Overall, the future outlook is promising but dependent on clinical validation, with the greatest potential likely to come from differentiated approaches that enable selective pathway modulation and rational integration with complementary therapeutic mechanisms.<\/i><\/p>\n<p align=\"justify\"><b>Recent Developments in the TGFb Inhibitor Treatment Space<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In September 2026, Keros Therapeutics, Inc. announced that it expects to receive a USD 20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase III, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (\u201cMF\u201d) and anemia on concurrent ruxolitinib therapy.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In April 2026, GSK plc announced the completion of its acquisition of 35Pharma Inc., a Canada-based, private, clinical-stage biopharmaceutical company specialising in the development of novel protein-based and TGF-beta superfamily therapeutics. The acquisition includes HS235, a potential best-in-class molecule for the treatment of pulmonary hypertension (PH). Under the terms of the agreement, GSK has acquired 100% of the equity of 35Pharma Inc. for USD 950 million.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In February 2026, Oncotelic Therapeutics, Inc. and Sapu Bioscience announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-\u03b2 antisense therapeutic platform, strengthening protection across neurology, oncology, and central nervous system (CNS) drug delivery.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In November 2025, Tiumbio Co., Ltd. shared the interim Phase II clinical data for its \u201cfirst-in-class\u201d Tosposertib (TU2218), a dual inhibitor against TGF\u03b2 type I receptor (TGF\u03b2RI \/ALK5) and VEGFR2. The study evaluated Tosposertib in combination with MSD&#8217;s Keytruda (pembrolizumab) as a first-line therapy for patients with recurrent\/metastatic(r\/m) head and neck squamous cell carcinoma (HNSCC).<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In September 2025, MedPacto, a Korean biotechnology company, launched a phase II clinical trial of its investigational drug vactosertib for osteosarcoma in Korea and the U.S.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In September 2025, Akeso Inc. has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independently developed TIGIT\/TGF-\u03b2 bifunctional antibody fusion protein, in combination with ivonescimab (PD-1\/VEGF bispecific antibody), for treating locally advanced or metastatic pancreatic cancer in patients who have failed up to two prior lines of systemic therapy.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In July 2025, Keros Therapeutics, Inc. announced that the first patient was dosed in the Phase III RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes (\u201cMDS\u201d). The dosing of the first patient triggers a USD 10 million milestone payment to Keros under the global license agreement with Takeda.<\/li>\n<\/ul>\n<p align=\"justify\"><b>Scope of the TGFb Inhibitors Pipeline Report\u00a0<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Coverage<\/b>:\u00a0Global\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>TGFb Inhibitors Therapeutic Assessment By Product Type: <\/b>Mono, Combination, Mono\/Combination<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>TGFb Inhibitors Therapeutic Assessment By Clinical Stages: <\/b>Discovery, Pre-clinical, Phase I, Phase II, Phase III<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>TGFb Inhibitors Therapeutics Assessment<\/b> <b>By Route of Administration:<\/b> Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>TGFb Inhibitors Therapeutics Assessment<\/b> <b>By Molecule Type<\/b>: Oligonucleotide, Peptide, Small molecule<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Key TGFb Inhibitors Companies<\/b>: Takeda, Hansoh Pharma, iOnctura, Sirnaomics, EpicentRx, Akeso Biopharma, Scholar Rock, Oncotelic Inc., MedPacto, Inc., and others<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Key Pipeline TGFb Inhibitors<\/b>: Elritercept\/HS-20106, IOA-359, STP707, AdAPT-001, AK130, SRK-181, OT-101, STP705, STP355, Vactosertib, and others<\/li>\n<\/ul>\n<p align=\"justify\">Dive deep into rich insights for new TGFb inhibitors, visit @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LowcUB4kr_TZV8TO1UQiXhhRKMh6SDP-1UmX_yHXnSaxpdL7SUK-Gewwb_zUc9gGkCYjGzd-jeYwfH3VevqAfAzh8eqJJr0aTckzh0jnOZ11xoHhvydLk9ixRISAZsydm52LJuEyZElneBbEw61CzdNGynmQB7YCTnpAJxk7DIHX4gD6zn8HnP7NAjTmtufUcCpMoRngszvZ9RsUnU5AhQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>TGFb Inhibitors Drugs<\/b><\/a><\/p>\n<p align=\"justify\"><b>Table of Contents<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">1.<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">TGFb Inhibitors Pipeline Report Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">TGFb Inhibitors Pipeline Report Executive Summary<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">3.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">TGFb Inhibitors Pipeline: Overview<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">4.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Analytical Perspective In-depth Commercial Assessment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">5.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">TGFb Inhibitors Clinical Trial Therapeutics<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">6.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">TGFb Inhibitors Pipeline: Late-Stage Products (Pre-registration)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">TGFb Inhibitors Pipeline: Late-Stage Products (Phase III)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">8.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">TGFb Inhibitors Pipeline: Mid-Stage Products (Phase II)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">9.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">TGFb Inhibitors Pipeline: Early-Stage Products (Phase I)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">10.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">TGFb Inhibitors Pipeline Therapeutics Assessment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">11.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Inactive Products in the TGFb Inhibitors Pipeline<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">12.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Company-University Collaborations (Licensing\/Partnering) Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">13.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Companies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">14.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Products in the TGFb Inhibitors Pipeline<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">15.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Unmet Needs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">16.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Market Drivers and Barriers<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">17.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Future Perspectives and Conclusion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">18.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Analyst Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">19.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Appendix<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">For further information on the TGFb inhibitors pipeline therapeutics, reach out @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LowcUB4kr_TZV8TO1UQiXvpvj8EPg4sZP7151ADOZcKa814YgyJCYcP5gfHtk4O6XOvRnd4mhhux28ZlG7-3J2SeWEuUB6FXWlEgoQ-44YN2dWVGWdA8iO8fy_BpvPvo9O7OzLjqvPre5AcjG-CR6EB7_9ilC_-fH8koC_gn_Uf14d04QJjykV6f2EqEf-SYlOEU3aOubWy5FiGFT7-1ghaCHbV_pzNnrb4yYXFCBY4=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>TGFb Inhibitors Therapeutics<\/b><\/a><\/p>\n<p align=\"justify\"><b>Related Reports<\/b><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WjVG1276gJBYe7clweYoIbuax9aASIQM-ccnGy6IEY4kHB5VsvN48sdsVBxfMbMgayRXfdJL2AHveKb16LAzVrj0tuHkuRFExXCXrSSZQtgzxzLBzdMKo2-aLAWkfNfC1uKat0QK3Yoru4tNz1LF0kjd7sbYvcYCnrV8kOALJAiJuFkLuHElkQ7ziZ_KNVpw9WQpF-yyu5K6bK592OfKzzh1dd1kYna1CHSv5LqtCCW9ivP0XJqjt_qfzhY60-jwVLlzbUi072HhBEcLD-8onz7lGZdFC0UCvdY7KWYTWRPOqOnbRFDckapPTbZg5b7T\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>TGF Inhibitors Clinical Trial Analysis<\/b><\/a><\/p>\n<p align=\"justify\"><b>TGF Inhibitors Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TGF inhibitors companies, including <b>MedPacto, EpicentRx, Sirnaomics, Scholar Rock, SiSaf, Isarna Therapeutics, Antisense Pharma, XOMA, Energenesis Biomedical, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RHY-eDk-506sjsk94dDLtxnKqWxDwAwzQtFuNulpOgnMdpUnhN35weaecEKO0M7w9-74D4fq06ZCak2DLxbsjXafWvZHS3iusve59BDV0mjs6BVSvqTAauUV34pCUmLU6kZZo5xyjbuLxurPkS5Et3xPD9BGXkDlPrfpSo3TIrhjHo5PE-R8-zzy-BsxVgqL9Eq-mSlY7JJ7g-yOhljo8GG4uVyK0IoL0KV-9Zat2JPy2SFmIJpVRMpYJHFxObnWtFLW-qzS7t9AvkZQNTHQFHF9Ft2YCF81S1NLVV7QRSI=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>TGF Beta 1 Inhibitors Clinical Trial Analysis<\/b><\/a><\/p>\n<p align=\"justify\"><b>TGF Beta 1 Inhibitors Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TGF beta 1 inhibitors companies, including <b>MedPacto, EpicentRx, Sirnaomics, Scholar Rock, SiSaf, Isarna Therapeutics, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RHY-eDk-506sjsk94dDLt1GmeMwxzxTXxaFHmEH22RBe23N0Akbzg0o9vewC8SfkeMy0chg_9xzXM8W8vLbiki3uu_dYJzUrBLGN7xXZI4C-ea0T3HuvX8O5vn3yXOnb6uqv0NBJaoI1xokj7_gWFK3sBsUQ1JPBirz5zJibvovxZX2NuMkwRfGQl7DQyLbd5cmrj8dpojTS4xr-rQu5dW5119ADZ7ERthOn5zo_JWrV4OSzduBfFvOrLOeqIpmohAUku_6BWJt0O_YgLf1O_swb0J5TG0WuFdT3mIecixY=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>TGF Beta 2 Inhibitors Clinical Trial Analysis<\/b><\/a><\/p>\n<p align=\"justify\"><b>TGF Beta 2 Inhibitors Pipeline Insight \u2013 2026<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TGF beta 2 inhibitors companies, including <b>Isarna Therapeutics, Antisense Pharma, XOMA, Energenesis Biomedical, <\/b>and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tmI5_uUmDOrvV-iCzhLPsNBiiR1P8bKiwl6DDpRHeHq7bd16URja5UKFdx_9pRSmE7BpMEynDX0PjaGI_uy2MapL2E5H21VwvQdLyP31DxYy5mfs9Lgg6g3gtyrDwsLt7YwH7LxxQ2_ulUJEYe-wuPHS3CUw1QaQ8SSniojDJuy22lSi_Lncw-Cr-hcOfxemySqO9O7LCYZrSoqTNi0mU1-0lZBK50Iirt3BRdPybwuc1aanUO_6MX1V87Y9Rh7NSSE-aSUlQj_7XeNNhQPWdA==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Glioblastoma Multiforme Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Glioblastoma Multiforme Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GBM companies, including <b>Avita Biomedical, TAE Life Sciences, Orbus Therapeutics, Chimerix, Laminar Pharma, Kazia Therapeutics, Precision NeuroMed, Imvax, Tilray, Medicinna Therapeutics, CNS Pharmaceuticals, Enterome, Northwest Biotherapeutics, Vigeo Therapeutics, VBI Vaccines, Immunomic Therapeutics,<\/b> and others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nv2PjgYRYBpCPXTfxl6S5EWv66jYucdbkQaRWrhwfjSM3CF-RyTTiXL-IX9IDbRWI_bXSm5el2EB5bqYcMrdusaRHXwQqh2Oj5mALi-LMCMPUBS2WF3ciU9SV6ffKKXok9eKbaX4l11F9Ixi0kCVpvnsvaS7cJkpF-oKRtaFCKdXaw5hk-OEpjRhM2yium-wqVOoSsu5v6496okZz1vuPCjHfZCztyhAcMtniSRNvYZnqISM3qwdWF2YSktQ3sPq\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Pancreatic Cancer Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast \u2013 2036 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pancreatic cancer companies including <b>AstraZeneca, Merck Sharp &amp; Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb, <\/b>and others.<\/p>\n<p align=\"justify\"><b>About\u00a0DelveInsight<\/b><\/p>\n<p align=\"justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve<b>.<\/b><\/p>\n<pre>CONTACT: Contact Us\n\nShruti Thakur\u00a0\n\ninfo@delveinsight.com\u00a0\n\n+14699457679<\/pre>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/NWE1NDFjMmUtZTA1OC00NTRlLTkyYjUtNTFhNzk1MjUzN2IxLTEyMDQ5MzgtMjAyNi0xMC0yNy1lbg==\/tiny\/DelveInsight-Business-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The TGFb inhibitor clinical trial analysis report delivers important insights into ongoing research on 30+ TGFb inhibitors in the pipeline, clinical strategies, upcoming therapeutics, and commercial analysis. New York, USA, Oct. 27, 2026 (GLOBE NEWSWIRE) &#8212; TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight\u00a0 The [&#8230;]\n","protected":false},"author":1,"featured_media":88852,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-88851","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The TGFb inhibitor clinical trial analysis report delivers important insights into ongoing research on 30+ TGFb inhibitors in the pipeline, clinical s\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-27T17:45:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-28T01:59:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/10\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight\",\"datePublished\":\"2026-10-27T17:45:00+00:00\",\"dateModified\":\"2026-10-28T01:59:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/\"},\"wordCount\":1683,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/\",\"name\":\"TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-10-27T17:45:00+00:00\",\"dateModified\":\"2026-10-28T01:59:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/","og_locale":"en_US","og_type":"article","og_title":"TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight","og_description":"The TGFb inhibitor clinical trial analysis report delivers important insights into ongoing research on 30+ TGFb inhibitors in the pipeline, clinical s","og_url":"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-10-27T17:45:00+00:00","article_modified_time":"2026-10-28T01:59:08+00:00","og_image":[{"width":800,"height":420,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/10\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight","datePublished":"2026-10-27T17:45:00+00:00","dateModified":"2026-10-28T01:59:08+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/"},"wordCount":1683,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/","url":"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/","name":"TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-10-27T17:45:00+00:00","dateModified":"2026-10-28T01:59:08+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/88851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=88851"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/88851\/revisions"}],"predecessor-version":[{"id":88853,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/88851\/revisions\/88853"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/88852"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=88851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=88851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=88851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}